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Abstract
Background: There is limited evidence about the anti-diabetic effects of selenium
supplementation in women with gestational diabetes mellitus (GDM).
Objective: This study investigates the effects of selenium supplementation on glucose
homeostasis in women with GDM.
Materials and Methods: A total of 60 pregnant women with GDM were enrolled in this
prospective randomized, double-blind, and placebo-controlled clinical trial. They were
randomly assigned to take either 100µg selenium supplements as tablet or a placebo
daily for 12 wk since 24-28 wk of gestation. The primary outcomes were changes in the
glucose homeostasis, including fasting plasma glucose, the 2-hr post prandial blood
glucose, serum insulin level, glycosylated hemoglobin (Hb A1C), and the homeostasis
model assessment of insulin resistance(HOMA_IR) at the initial period and 3 months
after intervention.
Results: The mean maternal age of the patients who took selenium supplements was
29.19 ± 6.16 (range 18-41) years. In the placebo group, the mean maternal age was 31 ±
4.43 (range 24-39) years. Compared with the placebo group, fasting plasma glucose, 2-
hr post-prandial blood glucose, glycosylated hemoglobin(Hb A1C), serum insulin level,
and homeostasis model of assessment-estimated insulin resistance(HOMA_IR) were
not significantly changed in the selenium group at the end of study (p = 0.25, p = 0.87,
p = 0.34, p = 0.57, and p = 0.31, respectively).
Conclusion: The results of this trial suggest that supplementation with 100µg of
selenium does not modulate glucose homeostasis in women with GDM.
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1. Introduction
Gestational diabetes mellitus (GDM) is a
temporary form of type 2 diabetes mellitus (T2DM)
and is one of the major health problems affecting
pregnant women (1). In fact, that is impaired insulin
metabolism and carbohydrate intolerance with
differing levels of severity for first time recognition
during pregnancy (2). In a normal pregnancy with
an increase in oxidative stress, insulin resistance
increases (3) and insulin secretion was decreased,
thus linking it to T2DM in some mothers (4).
Selenium, a dietary supplement, with antioxidant
action, which is required for the activity of
glutathione peroxidase (5). Dietary sources of
selenium is nuts, cereals, meat, mushrooms,
fish, and eggs (6). Being an essential element of
the enzymes, selenium protects cells from the
deleterious impact of free radicals (7, 8). Recent
evidence support the effective role of selenium
on hypertension (9), coronary artery disease (10),
some cancers (11), and inflammatory diseases
(12). Selenium may be involved in reducing
the severity of insulin resistance in diabetes
(13). Therefore, it appears to bear anti-diabetic
functions emerging from its insulin-like properties;
accordingly, selenium supplementation in diabetic
patient is likely to have beneficial effects on
glocuse utilization (14).
There are controversial results about the
association between selenium status and GDM.
Some investigations have proved pregnant
women with DM showing lower concentrations
of serum selenium in comparison with their
healthy counterparts (15). However, evidenced by
Molnar et al. (16), serum selenium concentration is
conspicuously higher in pregnant women with DM.
In another query, Al-Saleh et al. (17) failed to detect
a significant relationship between serum selenium
concentration and GDM. A recent clinical trial
evaluated the effects of selenium supplementation
on the metabolic profile of women with GDM (18).
The results demonstrated a considerable reduction
in the fasting plasma glucose (FPG), serum insulin
level, homeostasis model assessment of insulin
resistance (HOMA-IR).
Because of limited evidence about the anti-
diabetic effects of selenium supplementation
in women with GDM, our study was designed
to investigate the effects of selenium
supplementation on glucose homeostasis in
pregnant women with GDM.
2. Materials and Methods
2.1. Trial design
This study was designed as a prospective
randomized, double-blind, placebo-controlled,
clinical trial which was conducted on pregnant
women with GDM who were referred to the
outpatient clinic of Hafez and Zeinabieh hospital
(Shiraz, Iran) during a 16 month period from
December 2015 to March 2017.
2.2. Participants
A total of 60 consecutive pregnant women
aged between 18 and 40 yr with a diagnosis
of GDM by the 75-g oral glucose tolerance test
(OGTT) at 24 to 28-wk gestation who were carrying
singleton pregnancies were enrolled in the study.
The exclusion criteria included patients who
require substitute treatments, including hormones,
patients on oral hypoglycemic agents (OHAs), and
those who require insulin therapy. Patients with
hypo- or hyperthyroidism and smokers were also
excluded from the study. GDM was diagnosed
on the basis of the criteria set by the American
Diabetes Association (19). Specifically, those whose
plasma glucose meets one of the following criteria
were considered to have GDM: fasting ≥92 mg/dL,
1-hr after 75 gr glucose≥180 mg/dL, or 2-hr after 75
gr glucose ≥153 mg/dL.
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2.3. Interventions and outcomes
Women were randomly assigned to take either
100 µg selenium supplements as tablet or a
placebo daily for 12 wk beginning from the 24th to
the 28th wk of gestation. The shape and packing
of both tablets were similar to ensure double-
blind design. The prescribed selenium dose was
in accordance with the National Academy of
Sciences guidelines that established an upper
limit of 400 mg/d of selenium (20, 21). The
selenium and the matched placebo tablets were
purchased from pharma Nord company (Vejle,
Denmark). The placebo tablets contained Avicel
102 (microcrystalline cellulose). Both groups were
co-administered under an anti-diabetic diet by a
nutritionist and were recommended to do light
exercises.
We evaluated the patients’ fasting plasma
glucose (FPG) every 3 wk during the study period
to determine if any required insulin therapy so as to
exclude such patients from the study.
The baseline characteristics of the participants,
including maternal age, gestational age, height,
weight, and BMI were obtained by a data gathering
form. The main outcomes were the glucose
homeostasis changes including FPG, 2-hr post
prandial glucose (2HPPG) test with an enzymatic
method (glucose oxidase and peroxidase kits:
pars azmoon), serum insulin level by ECL method
(electrochemiluminescene kit: Immulit 2000),
HbA1c with the CERAGEM method (kit: cerastat
2000), HOMA-IR at the initial period and 3 months
after the intervention.








Healthy range: 1.0 (0.5-1.4); Less than 1.0: Insulin-
sensitive which is optimal; Above 1.9: Early insulin
resistance; Above 2.9: significant insulin resistance.
2.4. Randomization
Using a randomization table, randomization was
carried out based on the patient registration
number. Then blinded and labeled with a four-digit
code, study pills were packaged in separate packs.
The project coordinator maintained the information
in terms of the codes relating to a particular
treatment. All the patients, attending physicians,
staff involved in the study, and members garnering
and analyzing data were blinded to the intervention
other than the project coordinator.
2.5. Ethical consideration
The study protocol was approved by the
Institutional Review Board of SUMS and we
obtained Ethical Approval from the Local ethics
Committee (IR.SUMS.MED.REC.1395.13) before the
study was commenced. All the participants gave
their informed written consent.
2.6. Statistical analysis
The number of the samples used in this study
is based on data from previous studies and
the use of the MedCak software. A 90% power
and a 5% error were estimated for 27 persons
in each group. To shun the consequences of
possible attrition and exclusion from the study,
30 participants were enrolled in each group.
Statistical analyses were conducted deploying the
Statistical Package for Social Sciences version 19.0
(SPSS Inc., Chicago, IL, USA). Kolmogorov-Smirnov
test was employed to analyze the distribution of
the variable. The Chi-square (χ2) test was also
deployed to analyze nominal variables. Normally-
distributed Kolmogorov-Smirnov test parametric
variables were tested by independent Student’s
t-test. Non-normally-distributed metric variables
were also analyzed by Mann-Whitney U test. Data
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were then reported as means ± SD. A two-sided p-




Out of the 60 patients that were randomized
into the two study groups, six patients were
excluded. Four women from the selenium group
were excluded: one because of insulin therapy
while three were lost to follow-up. Two women in
the placebo group were excluded: one for preterm
labor pregnancy and one because OF high blood
sugar, she required insulin therapy. Ultimately, 26
patients were enrolled in the selenium group and
28 individuals were enrolled in the placebo group.
Figure 1 shows theConsort flowdiagramof this trial.
The baseline characteristics of the contributors
are shown in Table I, There were no significant
differences between the groups at baseline. The
mean maternal age, gestational age, and BMI
of the patients who consumed selenium and
the placebo group were the same. There were
no significant differences between the study
groups regarding gravidity and history of previous
abortions. Also, the number of gravida and history
of abortion among the participants in the selenium
and placebo groups are the same. In addition,
there were no differences in the parameters of
glucose homeostasis between the study groups at
baseline.
3.2. Outcomes of glucose
homeostasis
Compared with the placebo group, FPG, 2HPPG,
HbA1C, serum insulin, and HOMA-IR were not
significantly changed in the selenium group at the
end of study (p = 0.25, p = 0.87, p = 0.34, p = 0.57,
and p = 0.31, respectively) (Table II). In addition,
we evaluated the patients by FPG every 3 wk
during the study period. However, we did not find
any significant differences regarding FPG between
the study groups with the 3-wk intervals. Figure 2
shows the changing flow of FPG for each group.
In another analysis, we compared the changes
in the parameters of glucose homeostasis from
baseline between the groups. All of the parameters
decreased after 3 months in the two study groups
but in comparing these changes, they were not
significant (Table III). Finally, we did not find any
significant effect of taking selenium supplements
on FPG, 2HPPG, HbA1C, serum insulin, and HOMA-
IR.
Table I. Baseline characteristics of the participants
Selenium group (n = 26) Placebo group (n =28) p-value
Maternal age (years)*a 29.19 ± 6.16 31 ± 4.43 0.09
Gestational age (weeks)*a 27.15 ± 2.16 26.52 ± 1.91 0.31
Gravidity#b 0.29
Primigravida 11 (42.3) 8 (28.6)
Multigravida 15 (57.7) 20 (71.4)
History of previous abortion# b 5 (19.2) 6 (21.4) 0.84
BMI (kg/m2)*a 28.55 ± 3.76 28.03 ± 3.38 0.59
Glucose homeostasis*a
FPG (mg/dL)
88.73 ± 11.95 91.21 ± 8.21 0.37
OGTT-1hr (mg/dL) 186.15 ± 24.92 190.07 ± 20.85 0.53
OGTT-2hr (mg/dL) 149.15 ± 37.07 150.42 ± 16.84 0.87
HbA1c (%) 5.55 ± 0.59 5.34 ± 0.69 0.24
Serum Insulin (mIU/mL) 17.09 ± 6.91 15.15 ± 5.77 0.26
HOMA-IR 3.83 ± 1.71 3.29 ± 1.49 0.22
a: Data presented as Mean ± SD b: Data presented as n (%)
P<0.05 was considered significant *Student t-test
# Chi-square (χ2) test FPG: Fasting plasma glucose
OGTT: Oral glucose tolerance test
HOMA-IR: Homeostasis model of assessment-estimated insulin resistance
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Table II. Comparing glucose homeostasis variables between two study groups at the end of the study
Glucose homeostasis Selenium group (n = 26) Placebo group (n = 28) p-value
FPG (mg/dL)∗ 92.75 ± 9.21 83.51 ± 2.12 0.25
2HPPG (mg/dL)$ 136.21 ± 13.97 137.42 ± 24.04 0.87
HbA1c (%)$ 5.35 ± 0.54 5.31 ± 0.55 0.34
Serum insulin (mIU/mL)$ 15.96 ± 5.63 15.13 ± 4.89 0.57
HOMA-IR$ 3.37 ± 1.27 3.04 ± 1.09 0.31
Data presented as Mean ± SD A p-value of <0.05 was significant
*Student’s t-test $Mann-Whitney U test
FPG: Fasting plasma glucose 2HPPG: 2-hr post prandial glucose test
HOMA-IR: Homeostasis model assessment of insulin resistance
Table III. Comparing changes in glucose homeostasis parameters from baseline to 3 months
Glucose homeostasis Selenium group (n = 26) Placebo group (n = 28) p-value
FPG (mg/dL) 3.51 ± 1.22 -3.52 ± 3.53 0.49
2HPPG (mg/dL) -12.96 ± 8.91 -13 ± 7.54 0.95
HbA1c (%) -0.21 ± 0.43 -0.14 ± 0.25 0.51
Serum insulin (mIU/mL) -1.13 ± 3.81 -0.01 ± 2.58 0.33
HOMA-IR -0.45 ± 1.15 -0.25 ± 1.13 0.52
Data presented as Mean±SD A p-value <0.05 was significant (Mann-Whitney U test)
FPG: Fasting plasma glucose 2HPPG: 2-hr post prandial glucose test
HOMA-IR: Homeostasis model assessment of insulin resistance
Figure 1. Consort 2010 flow diagram.
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Figure 2. The changing flow of FPG for each group.
4. Discussion
Selenium is known as an essential trace
element bearing antioxidant activity as well as anti-
inflammatory effects (22). Decrease concentrations
of selenium in whole blood and plasma during
pregnancy is significant compared with pre-
pregnancy or non-pregnancy concentrations; with
the progression of gestation, this decrease in
selenium continues (23). Because of fetal growth,
there is a demand for selenium during pregnancy,
which projects as lowering maternal selenium
concentrations. These reductions are higher
in pregnant women suffering from gestational
diabetes (14, 24). In spite of such findings, few
clinical trials have investigated the efficacy of
selenium supplementation in controlling glucose
homeostasis in GDM. The results of our trial
suggest that taking 100µg selenium supplement
did not have significant effects on the FPG, 2HPPG,
HbA1C, serum insulin, and HOMA-IR of pregnant
women with GDM.
To the best of our knowledge, there has
been one report about the role of selenium
supplementation in GDM. Identified by their
method, Asemi et al. randomly categorized their
patients to administer either 200μg selenium
supplements (n = 35) or a placebo (n = 35) for
6 wk from wk 24 to wk 28 of gestation to their
patients (18). Their results demonstrated that
selenium supplementation in pregnant women
with GDM had a positive role in improving
glucose homeostasis, reducing inflammation,
and improving oxidative stress. However, it did
not affect the lipid profiles or plasma nitric oxide.
The results were in contrast with what was found
in our study. It is to be noted that in Asemi’s et al
trial, the participants’ dietary features and physical
activity records were established to ensure
maintenance of their routine diet and physical
activity during the research (18). Moreover, dietary
intakes of energy, carbohydrates, fatty acids,
proteins, cholesterol, total dietary fiber, selenium,
magnesium, and vitamins C, E, and A were finally
compared the results of which displayed no
significant differences. In our study, however,
participants were demanded to alter their routine
physical activity and usual dietary intakes; they
were required to consume the supplements only
provided by the investigators. Nevertheless, we
did not record and compare their dietary intakes.
This is an important limitation of this study and may
partly explain why the selenium supplementation
was ineffective for GDM. Another reason for the
difference between our results and that of Asemi
et al (18) can be attributed to the selenium dose.
They administrated 200 μg of selenium, whereas
we used 100 μg.
No side effects were fortunately reported
following selenium consumption in this study.
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Interestingly, supplemental selenium dose
deployed was lower than the upper limits (400
mg). However, there is controversy as to the
toxic impact of selenium on health. Earlier, Burk
et al. (25) reported an intake of moderate (200
mg/d) to large doses (600 mg/d) of selenium
supplements for 16 wk as safe in individuals aged
≥18 years. In another study, no considerable
escalation of the diabetes risk following selenium
supplementation was identified (26). However,
some investigations have enumerated hair loss,
dystrophic fingernail, gastrointestinal symptoms,
and memory impairment as the adverse effects
stemming from selenium intake (27). Moreover,
some studies demonstrate high selenium
intake likely having toxic effects on growth
hormone levels, insulin-like growth factor-1,
and thyroid function (28). Further queries are
accordingly required to appraise the potential
toxicity/teratogenicity of selenium supplements
intake in the long run.
Limitations
There are some limitations associated with
the present study. A major limitation is the
relatively few participants enrolled to observe the
differences in the primary endpoints. Therefore, the
conclusion can hardly be avoided as to the need
for validation of the relative effects of selenium
therapy through large-scale investigations.
Another limitation lies in not controlling the
impact of selenium supplementation on lipid
profiles, liver enzymes and kidney function as well
as on selenium-dependent antioxidant enzymes
such as GPx isoforms and thioredoxin reductase.
Additionally, as mentioned earlier, we did not
record and compare the dietary intakes of the
patients.
5. Conclusion
In summary, the results of this trial suggest
that supplementation with 100µg selenium has
no effect on glucose homeostasis in women with
GDM.
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